NZ600818A - Cyclic peptides for the regulation of vectorial ion channels - Google Patents

Cyclic peptides for the regulation of vectorial ion channels

Info

Publication number
NZ600818A
NZ600818A NZ600818A NZ60081811A NZ600818A NZ 600818 A NZ600818 A NZ 600818A NZ 600818 A NZ600818 A NZ 600818A NZ 60081811 A NZ60081811 A NZ 60081811A NZ 600818 A NZ600818 A NZ 600818A
Authority
NZ
New Zealand
Prior art keywords
amino acid
regulation
ion channels
cyclic peptides
terminally
Prior art date
Application number
NZ600818A
Other languages
English (en)
Inventor
Bernhard Fischer
Rudolf Lucas
Susan Tzotzos
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of NZ600818A publication Critical patent/NZ600818A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ600818A 2010-01-14 2011-01-12 Cyclic peptides for the regulation of vectorial ion channels NZ600818A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0004110A AT509267A1 (de) 2010-01-14 2010-01-14 Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PCT/AT2011/000014 WO2011085423A1 (de) 2010-01-14 2011-01-12 Zyklische peptide zur regulierung von vektoriellen ionenkanälen

Publications (1)

Publication Number Publication Date
NZ600818A true NZ600818A (en) 2014-02-28

Family

ID=43970939

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600818A NZ600818A (en) 2010-01-14 2011-01-12 Cyclic peptides for the regulation of vectorial ion channels

Country Status (16)

Country Link
US (1) US8754049B2 (enExample)
EP (1) EP2523968B1 (enExample)
JP (1) JP5771220B2 (enExample)
KR (1) KR101865420B1 (enExample)
CN (1) CN102770442B (enExample)
AT (1) AT509267A1 (enExample)
AU (1) AU2011206907B2 (enExample)
BR (1) BR112012017093A2 (enExample)
CA (1) CA2785185C (enExample)
DK (1) DK2523968T3 (enExample)
ES (1) ES2525381T3 (enExample)
IL (1) IL220924B (enExample)
NZ (1) NZ600818A (enExample)
PL (1) PL2523968T3 (enExample)
RU (1) RU2538597C2 (enExample)
WO (1) WO2011085423A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679239A1 (de) 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
CN105188734B (zh) * 2013-04-23 2019-03-01 阿佩普蒂科研究和开发有限责任公司 含有式x1-gqretpegaeakpwy-x2的环肽的冻干物
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
ES2813379T3 (es) * 2013-04-23 2021-03-23 Apeptico Forschung & Entwicklung Gmbh Tratamiento extracorporal del pulmón con un péptido cíclico de formula x1-gqretpegaeakpwy-x2
CA2939635A1 (en) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
WO2017046124A1 (en) * 2015-09-14 2017-03-23 Apeptico Forschung Und Entwicklung Gmbh Cyclic polypeptide for the treatment of pha type 1b

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
CZ302862B6 (cs) 1998-08-14 2011-12-21 Lécivo na lécení otoku
FR2839514A1 (fr) * 2002-05-07 2003-11-14 Centre Nat Rech Scient Nouveaux peptides cycliques, leur utilisation comme agents anti-microbiens
JP5108515B2 (ja) * 2004-08-06 2012-12-26 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺サーファクタント及びtnf由来ペプチドを含有する組成物
CN101007791A (zh) * 2007-01-12 2007-08-01 东华大学 一种氨基酸联苯化合物
CN101003520A (zh) * 2007-01-12 2007-07-25 陈志龙 一种缬氨酸丁酰联苯化合物
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
CN101298432B (zh) * 2008-05-30 2010-12-22 广州市星业科技发展有限公司 L-吡咯烷酮羧酸钠的制备方法
EP2296685B1 (en) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy

Also Published As

Publication number Publication date
EP2523968A1 (de) 2012-11-21
IL220924B (en) 2018-04-30
AU2011206907A1 (en) 2012-06-21
ES2525381T3 (es) 2014-12-23
US8754049B2 (en) 2014-06-17
CA2785185C (en) 2019-02-19
BR112012017093A2 (pt) 2016-11-29
RU2538597C2 (ru) 2015-01-10
AU2011206907B2 (en) 2016-06-02
HK1174341A1 (en) 2013-06-07
EP2523968B1 (de) 2014-09-10
DK2523968T3 (da) 2014-11-03
RU2012134322A (ru) 2014-02-20
JP2013517224A (ja) 2013-05-16
KR20120134100A (ko) 2012-12-11
CA2785185A1 (en) 2011-07-21
KR101865420B1 (ko) 2018-07-13
CN102770442A (zh) 2012-11-07
CN102770442B (zh) 2015-09-23
JP5771220B2 (ja) 2015-08-26
US20130072444A1 (en) 2013-03-21
AT509267A1 (de) 2011-07-15
PL2523968T3 (pl) 2015-03-31
WO2011085423A1 (de) 2011-07-21

Similar Documents

Publication Publication Date Title
NZ600731A (en) Oxyntomodulin peptide analogue
NZ600732A (en) Oxyntomodulin peptide analogue
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ618391A (en) Antigenic tau peptides and uses thereof
NZ704192A (en) Cell-penetrating peptides and uses therof
NZ609216A (en) Anticancer fusion protein
NZ607069A (en) Modified relaxin polypeptides and their uses
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
WO2009022157A3 (en) Peptide with improved solubility
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
EP3479824A3 (en) Peptides and their use
MX2010001856A (es) Proteina.
MX2014013333A (es) Variantes de enzima quimosina mejoradas.
NZ604412A (en) Vaccine and methods to reduce campylobacter infection
IN2014DN09367A (enExample)
MX2015001542A (es) Metodo.
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ598932A (en) Identification of antigenic peptides from multiple myeloma cells
IN2012DN05886A (enExample)
NZ596862A (en) Method for enhancing phagocytosis of phosphatidylserine-exposing cells by using annexin variants with added rgd sequences
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
NZ586074A (en) LCLRP peptides, constructs and uses thereof
EP3263123A3 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
WO2015015518A3 (en) Process for production of insulin and insulin analogues

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed